| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
- Topline Primary Endpoint Results of the Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia Following the 80th Event to Report this Month - |
| 12 Nov 2026 | 10-Q |
| 10 Nov 2026 | SCHEDULE 13G |
| 27 Oct 2026 | SCHEDULE 13G/A |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
–Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Following the 80th Event - |
| 11 Aug 2026 | 10-Q |
| 07 Aug 2026 | SCHEDULE 13G |
| 31 Jul 2026 | SCHEDULE 13G |
| 27 Jul 2026 |
8-K: Results of Operations and Financial Condition; Other Events
As of June 30, 2026, SELLAS Life Sciences Group, Inc. (the “Company”) estimates that its unaudited cash and cash equivalents position was $138.3 million. This amount is unaudited and preliminary and is subject to the completion of financ... |
| 25 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Re: Amended and Restated Severance and Change of Control Letter Agreement |
| 18 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 16, 2026, SELLAS Life Sciences Group, Inc. (the “Company”) held its Annual Meeting of Stockholders (“Annual Meeting”). There were 115,511,771 shares of common stock, or approximately 62.59% of all outstanding shares, present in p... |
| 18 Jun 2026 |
Form 4: Stergiou Angelos M., Director
Received 1,065,000 shares as a grant or award |
| 16 Jun 2026 | FORM S-8 |
| 02 Jun 2026 |
8-K: Other Events
As previously reported, as of March 31, 2026, SELLAS Life Sciences Group, Inc. (the “Company”) had $107.1 million of cash and cash equivalents. |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
– Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that 78 Events have Occurred in the Trial as of May 11, 2026; SELLAS Remains Blinded to Tri... |
| 12 May 2026 | 10-Q |
| 24 Apr 2026 | SCHEDULE 13G/A |
| 23 Apr 2026 | ARS |
| 23 Apr 2026 | DEFA14A |
| 23 Apr 2026 |
Proxy statement: annual meeting on June 16, 2026
CEO pay $1.9M, up 58% · say-on-pay vote |
Loading...